Abstract
The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.
Full Text
What is claimed is:
The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.
Timeline
Filed
04/09/2026Published
08/06/2026Granted
Not AvailableIPC Codes(4)
A61K 31/519:ortho- or peri-condensed with heterocyclic rings
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 47/02:Inorganic compounds